References
- Allen NE, Key TJ, Appleby PN, et al (2007). Serum insulin like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev, 16, 1121-7. https://doi.org/10.1158/1055-9965.EPI-06-1062
- Brawley OW (2012). Prostate cancer epidemiology in the United States3. World J Urol, 30, 195-200. https://doi.org/10.1007/s00345-012-0824-2
- Collett-Solberg PF, Cohen P (1996). The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am, 25, 591-614. https://doi.org/10.1016/S0889-8529(05)70342-X
- Chen C, Freeman R, Voigt LF, et al (2006). Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomarkers Prev, 15, 2461-6. https://doi.org/10.1158/1055-9965.EPI-06-0541
- Cheng I, Penney KL, Stram DO, et al (2006). Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev, 15, 1993-7. https://doi.org/10.1158/1055-9965.EPI-06-0361
- Costalonga EF, Antonini SR, Guerra-Junior G, et al (2009). The -202 A allele of insulin-like growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with evere growth hormone deWciency. J Clin Endocrinol Metab, 94, 588-95. https://doi.org/10.1210/jc.2008-1608
- DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials , 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
- Deal C, Ma J, Wilkin F, et al (2001). Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab, 86, 1274-80. https://doi.org/10.1210/jc.86.3.1274
- D'Aloisio AA, Schroeder JC, North KE, et al (2009). IGF-I and IGFBP- 3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev, 18, 954-66. https://doi.org/10.1158/1055-9965.EPI-08-0856
- Egger M, Davey Smith G, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
- Friedrichsen DM, Hawley S, Shu J, et al (2005). IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate, 65, 44-51. https://doi.org/10.1002/pros.20259
- Hankinson SE, Willett WC, Colditz GA, et al (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351, 1393-6. https://doi.org/10.1016/S0140-6736(97)10384-1
- Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
- Hernandez W, Grenade C, Santos ER, et al (2007). IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis, 28, 2154-9. https://doi.org/10.1093/carcin/bgm190
- Hoyo C, Grubber J, Demark-Wahnefried W, et al (2007). Gradespecific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. J Natl Med Assoc, 99, 718-22.
- Hong SK, Han BK, Jeong JS, et al (2008). Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men. Asian J Androl, 10, 207-13. https://doi.org/10.1111/j.1745-7262.2008.00296.x
- Johansson M, McKay JD, Rinaldi S, et al (2009). Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate, 69, 1281-91. https://doi.org/10.1002/pros.20972
- Kelley KM, Oh Y, Gargosky SE, et al (1996). Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol, 28, 619-37. https://doi.org/10.1016/1357-2725(96)00005-2
- Kolonel LN, Henderson BE, Hankin JH, et al (2000). A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol, 15, 346-7.
- Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6. https://doi.org/10.7326/0003-4819-127-9-199711010-00008
- Li L, Cicek MS, Casey G, Witte JS (2004). No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev, 13, 497-8.
- Li L, Huang X, Huo K (2010). IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep, 37, 127-40. https://doi.org/10.1007/s11033-009-9552-0
- Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
- Ma J, Pollak MN, Giovannucci E, et al (1999). Prospetive study of colorectal cancer risk in men and plasma levels of insulinlike growth factor(IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst, 91, 620-5. https://doi.org/10.1093/jnci/91.7.620
- Nam RK, Zhang WW, Trachtenberg J, et al (2003). Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev, 12, 1429-37.
- Neuhouser ML, Schenk J, Song YJ, et al (2008). Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate, 68, 1477-86. https://doi.org/10.1002/pros.20819
- Platz EA, Pollak MN, Leitzmann MF, et al (2005). Plasma insulinlike growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control, 16, 255-62. https://doi.org/10.1007/s10552-004-3484-8
- Pham TM, Fujino Y, Kikuchi S, et al (2007). A nested case-control study of stomach cancer and serum insulin-like growth factor (IGF)-1,IGF-2 and IGF-binding protein (IGFBP)-3. Eur J Cancer, 43, 1611-6. https://doi.org/10.1016/j.ejca.2007.04.014
- Park K, Kim JH, Jeon HG, et al (2010). Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urology, 75, e1-7. https://doi.org/10.1016/j.urology.2009.09.001
- Rohrbacher M, Risch A, Kropp S, et al (2005). The A(-336) C insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev, 14, 289-90.
- Schildkraut JM, Demark-Wahnefried W, Wenham RM, et al (2005). IGF1 (CA)19 repeat and IGFBP3-202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev, 14, 403-8. https://doi.org/10.1158/1055-9965.EPI-04-0426
- Severi G, Morris HA, MacInnis RJ, et al (2006). Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 15, 1137-41. https://doi.org/10.1158/1055-9965.EPI-05-0823
- Sarma AV, Dunn RL, Lange LA, et al (2008). Genetic polymorphisms in CYP17, CYP3A4,CYP19A1,SRD5A2,IGF- 1,and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate, 68, 296-305. https://doi.org/10.1002/pros.20696
- Schumacher FR, Cheng I, Freedman ML, et al (2010). A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet, 19, 3089-101. https://doi.org/10.1093/hmg/ddq210
- Safarinejad MR, Shafiei N, Safarinejad S (2011), Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3. Growth Horm IGF Res, 21, 146-54. https://doi.org/10.1016/j.ghir.2011.03.008
- Seligson DB, Yu H, Tze S (2012). IGFBP-3 Nuclear Localization Predicts Human Prostate Cancer Recurrence. Horm Cancer, 26, in press.
- Tobias A (1999). Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull, 8, 15-7.
- Wang L, Habuchi T, Tsuchiya N, et al (2003). Insulin-like growth factor-binding protein-3 gene 2202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res, 63, 4407-11.
- Wagner K, Hemminki K, Israelsson E, et al (2005). Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer. Breast Cancer Res Treat, 92, 133-40. https://doi.org/10.1007/s10549-005-2417-x
- Yu H, Spitz MR, Mistry J, et al (1999). Plasma levels of insulinlike growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst, 91, 151-6. https://doi.org/10.1093/jnci/91.2.151
- Zhang L, Yang BX, Zhang HT, et al (2011). Prostate cancer: an emerging threat to the health of aging men in Asia. Asian J Androl, 13, 574-8. https://doi.org/10.1038/aja.2010.126